-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Returning Diagnostic, Uncertain and Incidental Genomic Results to Physicians, Patients and Research Participants

Program: Spotlight Sessions
Session: Returning Diagnostic, Uncertain and Incidental Genomic Results
Sunday, December 6, 2015, 4:30 PM-6:00 PM
W314, Level 3 (Orange County Convention Center)

Sharon E Plon, MD, PhD

Baylor College of Medicine, Houston, TX; Texas Children's Cancer Center, Texas Children's Hospital, Houston, TX

Disclosures: Plon: Baylor Miraca Genetics Laboratories: Membership on an entity’s Board of Directors or advisory committees , Research Funding . Off Label Use: Crizotinib - for ALK rearranged or mutated tumors; Olaparib - tumors that have BRCA1/BRCA2 mutations or which demonstrate defective homologous recombination..

See more of: Returning Diagnostic, Uncertain and Incidental Genomic Results
See more of: Spotlight Sessions
Previous Presentation | Next Presentation >>